FindTrial
Sign In

Kyprolis 30 mg powder for solution for infusion

DRUG8 trials

Sponsors

F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, Celgene Corp., University Medical Center Hamburg-Eppendorf, Kite Pharma Inc., Medizinische Universitaet Innsbruck

Conditions

Multiple myelomaMultiple myeloma (MM)Multiple myeloma (MM) with at least 2 prior therapies including an immunomodulatory (IMiD) compound and a proteasome inhibitor (PI) and demonstrated disease progression on or within 60 days of completion of the last therapy.Relapsed Refractory Multiple MyelomaRelapsed or Refractory Multiple MyelomaRelapsed/refractory multiple myeloma in patients who have received 1 to 3 prior lines of therapy and have been exposed to both an immunomodulatory drug and an anti-CD38 monoclonal antibodymultiple myelomarelapsed/refractory multiple myeloma

Phase 1

An Open-label, Randomized Phase Ib/II Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants with Relapsed or Refractory Multiple Myeloma
CompletedCTIS2023-503689-21-00
F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AGMultiple myeloma (MM)
Start: 2023-12-05End: 2025-04-14Target: 73Updated: 2024-10-10

Phase 2

Daratumumab in combination with Carfilzomib, Pomalidomide and Dexamethasone (DCPD) in patients with multiple myeloma induced acute renal failure - "Time is Kidney in the Treatment of myeloma Cast nephropathy" The TIKTAC phase II trial (Pilot-study)
Not yet recruitingCTIS2024-514702-31-00
Medizinische Universitaet InnsbruckMultiple myeloma
Target: 50Updated: 2024-10-29

Phase 3

A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)
Active, not recruitingCTIS2023-509848-10-00
Celgene Corp.Multiple myeloma (MM) with at least 2 prior therapies including an immunomodulatory (IMiD) compound and a proteasome inhibitor (PI) and demonstrated disease progression on or within 60 days of completion of the last therapy.
Start: 2019-06-12Target: 138Updated: 2025-11-28
Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressive patients with multiple myeloma after a first-line therapy
CompletedCTIS2024-510590-14-00
University Medical Center Hamburg-Eppendorfmultiple myeloma
Start: 2023-03-03End: 2025-01-30Target: 400Updated: 2025-02-05
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
RecruitingCTIS2024-511188-26-00
Kite Pharma Inc.Relapsed/refractory multiple myeloma in patients who have received 1 to 3 prior lines of therapy and have been exposed to both an immunomodulatory drug and an anti-CD38 monoclonal antibody
Start: 2024-12-20Target: 192Updated: 2025-09-12
An Open-label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab plus Carfilzomib versus Standard of Care Combination Regimens in Patients with Relapsed/Refractory Multiple Myeloma
Not yet recruitingCTIS2024-519504-27-00
Regeneron Pharmaceuticals Inc.Relapsed Refractory Multiple Myeloma
Target: 40Updated: 2026-02-10
HO183 CAR T: A phase III randomized trial comparing academically produced BCMA-directed CAR T-cells (ARI0002h) with standard of care regimen in patients with relapsed/refractory multiple myeloma
Not yet recruitingCTIS2025-524876-43-00
Universitair Medisch Centrum Groningenrelapsed/refractory multiple myeloma
Target: 126Updated: 2026-04-29
A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, versus Standard Regimens in Participants with Relapsed Refractory Multiple Myeloma (DURGA-4)
Not yet recruitingCTIS2025-523285-25-00
AstraZeneca ABRelapsed or Refractory Multiple Myeloma
Target: 38Updated: 2026-04-30